{"product_id":"anti-claudin-18-isoform2-anti-cd3-igg-bispecific-antibody-bha18200076","title":"Anti-Claudin-18 Isoform2-Anti-CD3 IgG Bispecific Antibody","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\u003cdiv class=\"bhp-desc\"\u003e\n\u003cp class=\"bhp-cat-pill\"\u003eImmunotherapy\u003c\/p\u003e\n\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cp\u003eAnti-Claudin-18 isoform2 (CLDN18.2)-Anti-CD3 IgG format bispecific antibody is a purified recombinant human bispecific antibody with T cell Engager. This bispecific antibody has been tested for specific activity in the functional reporter assay using NFAT-luc reporter Jurkat cell line (BPS Bioscience #60621) in the presence of CLDN18.2-CHO cells (BPS Bioscience #78533-H) that overexpress CLDN18.2.\u003c\/p\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eClonality\u003c\/th\u003e\n\u003ctd\u003eMonoclonal (Bispecific)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eHost\u003c\/th\u003e\n\u003ctd\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAntibody Type\u003c\/th\u003e\n\u003ctd\u003eIgG1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eIsotype\u003c\/th\u003e\n\u003ctd\u003eIgG1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReactivity\u003c\/th\u003e\n\u003ctd\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePurification\u003c\/th\u003e\n\u003ctd\u003eProtein A affinity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e≥90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eMolecular Weight\u003c\/th\u003e\n\u003ctd\u003eTotal: 150 kDa (Heavy Chain: 50 kDa; Light Chain: 24 kDa)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003e8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003eAt least 12 months at -80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eValidated Applications\u003c\/h2\u003e\n\u003cul\u003e\u003cli\u003eReporter Assay\u003c\/li\u003e\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eAssay conditions:\u003c\/strong\u003e Experimental design and assay protocol for measuring anti-CLDN18.2-anti-CD3 functional activity using NFAT-luc reporter Jurkat cell line: Jurkat effector cells with endogenous TCR\/CD3 and transfected reporter NFAT-luc (BPS Bioscience #60621) are incubated with increasing concentrations of anti-CLDN18.2 x anti-CD3 bispecific antibody in the presence of CLDN18.2-CHO cells (BPS Bioscience #78533-H) or CHO cells (ATCC #CCL61™). 1. Seed CHO and CLDN18.2-CHO cells at 30,000 cells\/well and allow a few hours for the cells to attach in a 96-well clear bottom white plate. 2. Seed Jurkat cells at 30,000 cells\/well. 3. Add the bispecific antibody at a recommended dilution range of 100 fM-100 nM. The bispecific antibody simultaneously binds to TCR\/CD3 on the NFAT-luc Jurkat reporter cells and tumor antigen CLDN18.2 on CLDN18.2-CHO cells. 4. After 16 hours the luciferase activity is measured using ONE-Step™ Luciferase Assay (BPS Bioscience #60690) per recommended protocol. The bispecific antibody interaction stimulates NFAT-luciferase activity.\u003c\/p\u003e\n\u003ch2\u003eImmunogen \/ Antigen Information\u003c\/h2\u003e\n\u003cp\u003eImmunogen information not provided. Please refer to the product datasheet for detailed antigen information.\u003c\/p\u003e\n\u003ch2\u003eCross-Reactivity \u0026amp; Specificity\u003c\/h2\u003e\n\u003cp\u003eCross-reactivity data: Species reactivity as listed. No additional cross-reactivity data is available from the manufacturer.\u003c\/p\u003e\n\u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n\u003cdiv class=\"bhp-warning-box\"\u003e\n\u003cstrong\u003eBiosafety Level:\u003c\/strong\u003e Not applicable (BSL-1)\u003c\/div\u003e\n\u003cp\u003eAvoid freeze\/thaw cycles.\u003c\/p\u003e\n\u003cp\u003eFor Research Use Only (RUO). Not for diagnostic, therapeutic, or clinical use. Handle with standard laboratory precautions (gloves, safety glasses, lab coat). Avoid freeze-thaw cycles. Consult SDS prior to use.\u003c\/p\u003e\n\u003ch2\u003eRelated Products\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e78361\u003c\/li\u003e\n\u003cli\u003e78527\u003c\/li\u003e\n\u003cli\u003e78533\u003c\/li\u003e\n\u003cli\u003e101565\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e","brand":"BPS Bioscience","offers":[{"title":"50 ug","offer_id":53327924199789,"sku":"101541-1","price":410.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53327934456173,"sku":"101541-2","price":515.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/101541_gel.png?v=1778728311","url":"https:\/\/www.ebiohippo.com\/products\/anti-claudin-18-isoform2-anti-cd3-igg-bispecific-antibody-bha18200076","provider":"BioHippo","version":"1.0","type":"link"}